Head-to-head evidence
Bortezomib vs Carfilzomib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: Proteasome · full Multiple Myeloma pipeline
Bortezomib
Marketed by Takeda Pharmaceutical Company
NCT00048230 · Phase 3 · completed
Although the record states that participants were randomized, it also describes a single-group, unmasked study and does not document the high-dose dexamethasone comparator in the listed arms. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: October 2026 · NCT06140966 (registry estimate)
Carfilzomib
Marketed by Amgen and partners
NCT01080391 · Phase 3 · completed
The 792 participants were randomly assigned to carfilzomib plus lenalidomide and dexamethasone or to lenalidomide and dexamethasone, but treatment was open-label rather than blinded. The primary clinical endpoint, progression-free survival, was met, with a median of 26.3 versus 17.6 months and a statistically significant difference (p<0.0001).
Next expected readout: October 2026 · NCT06140966 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bortezomib's landscape · Carfilzomib's landscape